Small Business

Biocon launches long acting insulin substitute

Biocon Limited, India"s second largest bio-technology firm, has announced the launch of Basalog, a human insulin analogue, which attempts to relieve diabetic patients of frequent insulin shots in a day. - US consulate denies H1B visa curtailment for Indians - GVK Bio ties up with Chinese firm for clinical trials - Mahyco to focus on abiotic-stress resistant seeds - Biocon opens new research facility in B"lore - Avesthagen ties up with Chilean biotech firm - State set to revise biotech policy According to Biocon, this new product is effective for 24 hours. The company which is primarily focussing on finding diabetes and cancer care drugs, is parallely working on oral insulin which will further alleviate the trauma of diabetic patients having to take frequent injections of insulin substitute. The new offering while being effective for 24 hours will also help in avoiding low blood sugar, and better glucose control in the body.

Add your comment:

Name:
Site address:	http://
Your message:
Enter today\\\\'s date, 2 digits (spam protection):